1: Pereira DY, Yip AT, Lee BS, Kamei DT. Modeling mass transfer from carmustine-loaded polymeric implants for malignant gliomas. J Lab Autom. 2014 Feb;19(1):19-34. doi: 10.1177/2211068213499157. Epub 2013 Aug 23. Review. PubMed PMID: 23975389.
2: Gutenberg A, Lumenta CB, Braunsdorf WE, Sabel M, Mehdorn HM, Westphal M, Giese A. The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience. J Neurooncol. 2013 Jun;113(2):163-74. doi: 10.1007/s11060-013-1110-x. Epub 2013 Mar 28. Review. PubMed PMID: 23535992.
3: Dixit S, Hingorani M, Achawal S, Scott I. The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. Br J Neurosurg. 2011 Aug;25(4):459-69. doi: 10.3109/02688697.2010.550342. Epub 2011 Feb 23. Review. PubMed PMID: 21344976.
4: Nagaiah G, Almubarak M, Khan M, Altaha R. Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature. Cancer Invest. 2010 Dec;28(10):1048-53. doi: 10.3109/07357907.2010.483499. Epub 2010 Sep 27. Review. PubMed PMID: 20873990.
5: Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr Med Res Opin. 2008 Nov;24(11):3239-57. doi: 10.1185/03007990802508180 . Epub 2008 Oct 20. Review. PubMed PMID: 18940042.
6: Lin SH, Kleinberg LR. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther. 2008 Mar;8(3):343-59. doi: 10.1586/14737140.8.3.343. Review. PubMed PMID: 18366283.
7: Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review. PubMed PMID: 17999840.
8: Zackheim HS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. Dermatol Ther. 2003;16(4):299-302. Review. PubMed PMID: 14686972.
9: Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet. 2002;41(6):403-19. Review. PubMed PMID: 12074689.
10: Weiss RB, Issell BF. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev. 1982 Dec;9(4):313-30. Review. PubMed PMID: 6762924.  

Chemical
CAS Num	154-93-8
Chemical Formula	C5H9Cl2N3O2
Molecular Weight	214.05
IUPAC Chemical Name	1,3-bis(2-chloroethyl)-1-nitrosourea
Exact Mass	213.00718
Elemental Analysis	C, 28.06; H, 4.24; Cl, 33.13; N, 19.63; O, 14.95
Synonym	Synonyms
Solubility	Soluble in DMSO, not in water
SMILES Code	O=C(NCCCl)N(CCCl)N=O
Biological
Targets and Effects	N/A
Pathways	alkylating agent
Physical
Appearance	Solid powder
Purity	>98% (or refer to the Certificate of Analysis)
Shipping Condition	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition	Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Shelf Life	>2 years if stored properly